Sanofi SAN.PA
What does Sanofi do?
Sanofi is a globally active pharmaceutical group headquartered in Paris. The company researches, develops, produces and sells prescription medicines and vaccines. The focus is on immunology and inflammatory diseases, rare diseases, neurology and oncology. It also has a large vaccines division, which includes influenza, pediatric and combination vaccines as well as protection against respiratory syncytial virus.
Sanofi generates revenue mainly through the sale of patent-protected medicines and vaccines to hospitals, pharmacies, wholesalers, and government health systems and vaccination programs. Established medicines and over-the-counter health products also form part of the portfolio. In terms of competition, Sanofi is among the large diversified pharmaceutical companies and is one of the world's leading vaccine providers. New active ingredients come from its own research and from collaborations and licensing agreements with biotechnology companies.
Score profile
Rank vs. Drug Manufacturers - General (18 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Sanofi ranks below average in the group Drug Manufacturers - General (3.6/10). On growth, the company ranks among the best in the group Drug Manufacturers - General (8.6/10). On valuation (higher = cheaper), the stock ranks among the best in the group Drug Manufacturers - General (8.3/10). On financial strength, Sanofi ranks above average in the group Drug Manufacturers - General (6.9/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 9.3x | 15.9x | better than 92 % |
| Trailing P/E | 25.3x | 26.9x | better than 66 % |
| PEG ratio | 1.8x | 3.3x | better than 79 % |
| EV/EBITDA | 8.1x | 13.6x | better than 81 % |
| Price/sales | 2.1x | 4.2x | better than 81 % |
| Price/book | 1.4x | 5.5x | better than 97 % |
| Revenue growth | 15.7% | 5.8% | better than 92 % |
| Earnings growth | 9.4% | -2.8% | better than 79 % |
| Gross margin | 74.3% | 74.2% | better than 53 % |
| Operating margin | 22.3% | 31.5% | better than 19 % |
| Net margin | 8.2% | 14.3% | better than 36 % |
| Return on equity | 5.7% | 20.2% | better than 36 % |
| Debt/equity | 27.1% | 105.3% | better than 92 % |
| Current ratio | 1.1x | 1.4x | better than 36 % |
| Free cash flow yield | 7.9% | 3.8% | better than 81 % |
| Dividend yield | 4.7% | 2.3% | – |
| Payout ratio | 119.1% | 63.3% | – |
| Beta | 0.26 | 0.31 | – |
Valuation: what is Sanofi worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Sanofi a model range of 150.41 EUR to 217.42 EUR per share.
23 analysts, average rating “Buy”, average price target 96.36 EUR (+10.0%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Success depends heavily on the market penetration of key patent-protected medicines, particularly in immunology.
- The vaccines business benefits from government vaccination programs, seasonal demand and its position as an established large-scale provider.
- A well-stocked development pipeline and successful approvals secure long-term replacements for products whose patent protection is expiring.
Risks
- Patent expirations and competition from generics or biosimilars can significantly reduce revenue from established medicines.
- Clinical trials or approval procedures can fail, which writes off high research investments.
- Price regulation, reimbursement rules and political intervention in health systems weigh on pricing, especially in the US and Europe.
What to look for with Sanofi
The development of the revenue share of core products relative to the pipeline is informative, as it shows dependence on individual medicines and the need for replacements.